MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTX Stock Price Chart Interactive Chart >
MGTX Price/Volume Stats
| Current price | $15.36 | 52-week high | $18.45 |
| Prev. close | $15.01 | 52-week low | $11.35 |
| Day low | $14.49 | Volume | 356,700 |
| Day high | $15.50 | Avg. volume | 103,455 |
| 50-day MA | $14.09 | Dividend yield | N/A |
| 200-day MA | $14.45 | Market Cap | 680.17M |
MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio
MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.
Latest MGTX News From Around the Web
Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
MeiraGTx Announces Participation at Upcoming Investor ConferencesLONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May. BofA Securities 2021 Virtual Health Care ConferenceWednesday, May 12, 2021, 1:15 p.m. ET 2021 RBC Capital Markets Global Healthcare ConferenceWednesday, May 19, 2021, 4:50 p.m. ET Oppenheimer's Rare & Orphan Disease SummitFriday, May 21, 2021 (1x1 meetings only) Live webcasts of the presentations (where applicable) will be on the Investors page of the Company’s website at www.investors.meiragtx.com. For conferences that offer replays, presentations will be made available for a limited time. About MeiraG... |
MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon |
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021 LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress. “MeiraGTx experienced another year of significant progress in 2020 as we adva... |
MeiraGTx to Present at the 2021 Barclays Global Healthcare ConferenceLONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 30 days following the presentation. About MeiraGTxMeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core cap... |
Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q4 Earnings Expected to DeclineMeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
MGTX Price Returns
| 1-mo | 17.25% |
| 3-mo | -4.18% |
| 6-mo | -12.73% |
| 1-year | 9.71% |
| 3-year | 6.96% |
| 5-year | N/A |
| YTD | 1.45% |
| 2020 | -24.38% |
| 2019 | 107.68% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...